Known targets — ChEMBL curated mechanism
ACHECHRM1DRD1DRD2HTR2AHTR2BHTR2CMAOA
The experimentally established mechanism targets of Minaprine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE known ✓ | P22303 | 5/20 | 1.00 |
| ▸ | CHRM1 known ✓ | P11229 | 2/20 | 1.00 |
| ▸ | HTR2B known ✓ | P41595 | 1/20 | 1.00 |
| ▸ | LMNA | P02545 | 2/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 2/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 1/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 1/20 | 1.00 |
| ▸ | CNR1 | P21554 | 1/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 1/20 | 1.00 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Minaprine SCHEMBL124094 | 0.99 | CYP3A4 (1.00) | ACHELMNACYP3A4CHRM1CYP1A2 | |
| Minaprine SCHEMBL124092 | 0.99 | CYP3A4 (1.00) | ACHELMNACYP3A4CHRM1CYP1A2 | |
| Minaprine SCHEMBL124093 | 0.98 | ACHE (0.95) | ACHELMNACYP3A4CHRM1CYP1A2 | |
| Moxiraprine SCHEMBL635650 | 0.88 | ACHE (0.80) | ACHELMNACYP3A4CHRM1CYP1A2 | |
| SCHEMBL1752978 | 0.88 | LMNA (0.80) | ACHELMNACYP3A4CHRM1CYP1A2 | |
| SCHEMBL31759026 | 0.88 | ACHE (0.82) | ACHELMNACYP3A4CHRM1CYP1A2 | |
| SCHEMBL1752900 | 0.88 | ACHE (1.00) | ACHELMNACYP3A4CHRM1CYP1A2 | |
| SCHEMBL10744195 | 0.88 | ACHE (0.78) | ACHELMNACYP3A4CHRM1CYP1A2 | |
| SCHEMBL10748868 | 0.86 | ACHE (0.77) | ACHELMNACYP3A4CHRM1CYP1A2 | |
| SCHEMBL1752907 | 0.86 | ACHE (0.78) | ACHELMNACYP3A4CHRM1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 3583 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260001942-A1 | TREATMENT OF HEADACHE DISORDERS AND/OR PSYCHIATRIC SYMPTOMS USING ANTI-CGRP ANTIBODIES, AND COMPOSITIONS AND METHODS RELATED THERETO | H LUNDBECK AS (DK) | 2026-01-01 | — | — | US | claimed |
| WO-2025262247-A1 | TREATMENT OF HEADACHE DISORDERS AND/OR PSYCHIATRIC SYMPTOMS USING ANTI-CGRP ANTIBODIES, AND COMPOSITIONS AND METHODS RELATED THERETO | H. LUNDBECK A/S (DK) | 2025-12-26 | — | — | WO | claimed |
| US-20250339403-A1 | Tryptamine Formulations and Uses Thereof | Natural MedTech Pty Ltd (AU) | 2025-11-06 | — | — | US | claimed |
| EP-4633638-A1 | TREATMENT OF PSYCHOLOGICAL FACTORS AFFECTING OTHER MEDICAL CONDITIONS (PFAOMC) | Luminous Mind Inc. (US) | 2025-10-22 | — | — | EP | claimed |
| EP-4615444-A1 | TRYPTAMINE FORMULATIONS AND USES THEREOF | Natural Medtech Pty Ltd (AU) | 2025-09-17 | — | — | EP | claimed |
| WO-2025151884-A1 | USE OF GLYCOSAMINOGLYCAN SULFATED POLYSACCHARIDES SUCH AS SODIUM PENTOSAN POLYSULFATE IN COMBINATION WITH PERMEATION AGENTS TO TREAT ALZHEIMER'S DISEASE | PARSONS C LOWELL (US) | 2025-07-17 | — | — | WO | claimed |
| WO-2025101983-A1 | NON-STEROIDAL ISONITRILE BINDING COMPOUNDS OF CYTOCHROME P450 SUBTYPES | BRANDEIS UNIVERSITY (US) | 2025-05-15 | — | — | WO | claimed |
| EP-4536210-A2 | FLAVONOID COMPOUNDS AND METHODS AND MATERIALS FOR USING FLAVONOID COMPOUNDS TO TREAT FIBROTIC CONDITIONS | Mayo Foundation for Medical Education and Research (US) | 2025-04-16 | — | — | EP | claimed |
| CN-119231594-A | Electric automobile power distribution method based on micro-grid power quality state | 湖南工程学院 | 2024-12-31 | — | — | CN | claimed |
| EP-4479032-A1 | NEUROACTIVE STEROIDS FOR TREATMENT OF CNS-RELATED DISORDERS | Sage Therapeutics, Inc. (US) | 2024-12-25 | — | — | EP | claimed |
| JP-H09503491-A | — | — | 1997-04-08 | — | — | JP | claimed |
| CN-1129942-A | Aza spiro-compounds acting on the cholinergic system with muscarinic agonist activity | ISRAEL INST BIOLOG RES (IL) | 1996-08-28 | — | — | CN | claimed |
| EP-0711292-A1 | AZA SPIRO COMPOUNDS ACTING ON THE CHOLINERGIC SYSTEM WITH MUSCARINIC AGONIST ACTIVITY | KOSMIN, Gerald, Emmanuel (GB) | 1996-05-15 | — | — | EP | claimed |
| WO-1995003303-A2 | AZA SPIRO COMPOUNDS ACTING ON THE CHOLINERGIC SYSTEM WITH MUSCARINIC AGONIST ACTIVITY | STATE OF ISRAEL, REPRESENTED BY THE PRIME MINISTER'S OFFICE, ISRAEL INSTITUTE FOR BIOLOGICAL RESEARCH (IL) | 1995-02-02 | — | — | WO | claimed |
| EP-0452101-A2 | Spiro bridged and unbridged heterocyclic compounds | ISRAEL INSTITUTE FOR BIOLOGICAL RESEARCH (IL) | 1991-10-16 | — | — | EP | claimed |
| US-5053412-A | Central nervous system disorders | ISRAEL INSTITUTE FOR BIOLOGICAL RESEARCH (IL) | 1991-10-01 | — | — | US | claimed |
| US-4238489-A | 3-MORPHOLINOETHYLAMINO-4-METHYL-6-PHENYLPYRIDAZINE | C.M. INDUSTRIES (FR) | 1980-12-09 | — | — | US | claimed |
| US-4232020-A | 3-MORPHOLINOETHYLAMINO-4-METHYL-6-PHENYLPYRIDAZINE | C M INDUSTRIES (FR) | 1980-11-04 | — | — | US | claimed |
| US-4232019-A | 3-MORPHOLINOETHYLAMINO-4-METHYL-6-PHENYLPYRIDAZINE; ORAL | SOCIETE ANONYME DITE: CM INDUSTRIES (FR) | 1980-11-04 | — | — | US | claimed |
| US-4169158-A | Pyridazine derivatives in alleviating depressive states | CENTRE D'ETUDES EXPERIMENTALES ET CLINIQUES DE PHYSIO BIOLOGIE DE PHARMACOLOGIE ET D'EUTONOLOGIE (FR) | 1979-09-25 | — | — | US | claimed |